Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.
- Address
- lock Available on a paid plan
Gastroenterology and Inflammatory Bowel Disease
At Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o., a major share of research focuses on digestive system diseases, especially Crohn’s disease and ulcerative colitis. These studies aim to assess new treatment options, improve symptom control, and better understand long-term disease management in people living with chronic intestinal inflammation.
- Clinical research in inflammatory bowel disease, including Crohn’s disease and ulcerative colitis
- Studies testing therapies to improve remission and reduce intestinal inflammation
- Work on treatment options for difficult-to-control and pediatric forms of bowel disease
This is one of the site’s strongest therapeutic areas, with repeated emphasis on both effectiveness and longer-term control of gastrointestinal disorders.
Dermatology and Skin Disease
The site also conducts extensive trials in skin and connective tissue diseases, with research centered on atopic dermatitis, psoriasis, hidradenitis suppurativa, acne vulgaris, and related inflammatory skin conditions. The main purpose is to evaluate new therapies that may improve skin symptoms, reduce flare-ups, and support long-term disease control.
- Studies in atopic dermatitis, plaque psoriasis, and chronic hand eczema
- Research on hidradenitis suppurativa, prurigo nodularis, and acne vulgaris
- Trials exploring better symptom relief and sustained skin improvement
This area reflects a strong focus on chronic, often visible skin disorders that can significantly affect daily comfort and quality of life.
Autoimmune and Immune-Mediated Disorders
Research at the site includes a broad set of immune system diseases and autoimmune conditions, such as vitiligo, alopecia areata, and systemic lupus erythematosus. These trials generally aim to test whether newer treatments can better control immune-driven disease activity and improve visible or symptomatic outcomes.
- Trials in non-segmental vitiligo and alopecia areata
- Studies in systemic lupus erythematosus and cutaneous lupus-related disease
- Research focused on immune modulation and disease improvement over time
The site’s work in this field highlights efforts to address conditions where the immune system plays a central role in ongoing tissue damage or pigment loss.
Cardiometabolic and Endocrine Research
Another important area covers cardiovascular diseases, nutritional and metabolic diseases, and hormonal diseases. Trials here include hypertension, hypertriglyceridemia, obesity, osteoporosis, and menopause-related symptoms, with the goal of improving risk reduction, metabolic control, and overall patient well-being.
- Studies in hypertension, high cardiovascular risk, and established heart disease
- Research on hypertriglyceridemia, obesity, and related metabolic conditions
- Trials addressing osteoporosis and hormone-related symptoms
These studies support better management of long-term conditions that often overlap and influence one another.
Renal, Respiratory, and Other Specialized Conditions
The research portfolio at Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o. also includes studies in respiratory tract diseases, musculoskeletal diseases, and selected pathological conditions. Examples include chronic obstructive pulmonary disease, bronchiectasis, kidney disease, and endometriosis, reflecting a broad clinical interest beyond the site’s main inflammatory specialties.
- Trials in chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis
- Studies involving chronic kidney disease, IgA nephropathy, and other renal disorders
- Research on endometriosis and pain-related gynecologic conditions
These projects broaden the site’s clinical research activity across several important specialty areas while continuing to focus on practical treatment improvement.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 12 therapeutic areas and 15 of 77 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 74 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 29 by active trials.
- 1Eli Lilly & Co.6active
lock +28 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International11trials
lock +24 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.
lock Showing 1 of 116 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO). | AstraZeneca AB | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 77 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 9 | Unknown | 2018-07-26 | 2026-05-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
